WA-PHYSIO-CONTROL
RAV Utrecht (RAVU), the Utrecht Regional Ambulance Service, has announced that it will equip its entire emergency response fleet with LIFEPAK 15 monitor/defibrillators from Physio-Control .
The LIFEPAK 15 monitor/defibrillator is the industry leader and offers clinical efficacy, operational efficiency and excellent usability. For more than twenty years, RAVU’s emergency medical services have used LIFEPAK devices. Throughout the collaboration, Physio-Control has partnered to support the central pillars of RAVU’s service: patient-centered care, training and research.
“The LIFEPAK devices are familiar to our teams, the enhanced interfaces build upon earlier generations of LIFEPAK devices while adding important functions. They will allow for smooth transition training when they are implemented,” said Adrie Duizendstra, RAVU Facility Manager. “They are as easy to use as ever but are now more feature-rich. They are highly compatible with our electronic patient care reporting system, a feature which will make our response teams more efficient.”
“We are honored to be continuing our long-standing relationship with RAVU,” said Dré Quirijns, Physio-Control Benelux business manager. “For more than twenty years now, we have been providing RAVU with the latest technology to help them support clinical excellence and their world-class ambulance service.”
In addition to using LIFEPAK monitor/defibrillators, RAV Utrecht was also an early adopter of the Physio-Control LUCAS ® chest compression system. Performing AHA/ERC guideline-consistent chest compressions at 100 compressions per minute to a depth of 2”, LUCAS can be deployed quickly with minimal interruption to patient care. RAVU participated in a recent large randomized LINC (LUCAS In Clinical Action) clinical study led by the University of Uppsala, which compared the effectiveness of Physio-Control’s LUCAS mechanical chest compression system to high-quality manual chest compressions. Having studied and pioneered with the device for several years, RAVU are now sharing best practices with other Dutch regional ambulance systems.
“We aim to support RAVU with a complete systems approach,” said Mathieu Badard, Physio-Control Vice President and General Manager, EMEA and South Asia. “LIFEPAK monitor/defibrillators and the LUCAS chest compression system are all part of a complete system of care – a full range of resuscitation capabilities and services that we offer to our customers in order to support them in their lifesaving work.”
About the LIFEPAK ® 15 Monitor/Defibrillator
The LIFEPAK® 15 monitor/defibrillator is the standard in emergency care for advanced life support teams who want clinically innovative, operationally effective, and LIFEPAK TOUGH™ devices. More information at: www.physio-control.com/lifepak15
About Physio-Control
Physio-Control, Inc., headquartered in Redmond, Wash., USA, was founded in 1955, operates in over 100 countries and is the world’s leading provider of professional emergency medical response solutions that predict or intervene in life-threatening emergencies. The company’s products include LIFEPAK® monitor/defibrillators and automated external defibrillators, the LIFENET® System, HealthEMS® electronic patient care reporting (ePCR) software, LUCAS® 2 Chest Compression System, TrueCPRTM coaching device and implementation for PulsePoint bystander response applications. Learn more at www.physio-control.com , or via www.facebook.com/physiocontrolinc , https://www.linkedin.com/company/physio-control-inc- and Twitter: @PhysioControl .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150113005195/en/
Contact:
Physio-Control (USA)
Matt Fikse, +1 425-867-4208
matt.fikse@physio-control.com
or
OTTO
PR (EU)
Shaun Wootton, +44 (0)7796 338360
shaun@ottopr.co.uk
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum